# Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

> **NCT03766607** · PHASE2 · WITHDRAWN · sponsor: **Korean South West Oncology Group**

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03766607
- **Lead sponsor:** Korean South West Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-30
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Competing other studies
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03766607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03766607, "Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03766607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*